PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Nat Genet. Author manuscript; available in PMC 2011 October 1.
Published in final edited form as:
Published online 2010 September 19. doi:  10.1038/ng.669
PMCID: PMC3130795
NIHMSID: NIHMS287057

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population

Antonis C Antoniou,1 Xianshu Wang,2 Zachary S Fredericksen,3 Lesley McGuffog,1 Robert Tarrell,3 Olga M Sinilnikova,4,5 Sue Healey,6 Jonathan Morrison,1 Christiana Kartsonaki,1 Timothy Lesnick,3 Maya Ghoussaini,6 Daniel Barrowdale,1 EMBRACE,1,133 Susan Peock,1 Margaret Cook,1 Clare Oliver,1 Debra Frost,1 Diana Eccles,7 D Gareth Evans,8 Ros Eeles,9 Louise Izatt,10 Carol Chu,11 Fiona Douglas,12 Joan Paterson,13 Dominique Stoppa-Lyonnet,14 Claude Houdayer,14 Sylvie Mazoyer,5 Sophie Giraud,4 Christine Lasset,15,16 Audrey Remenieras,17 Olivier Caron,18 Agnès Hardouin,19 Pascaline Berthet,19 GEMO Study Collaborators,20,133 Frans B L Hogervorst,21 Matti A Rookus,22 Agnes Jager,23 Ans van den Ouweland,24 Nicoline Hoogerbrugge,25 Rob B van der Luijt,26 Hanne Meijers-Heijboer,27 Encarna B Gómez García,28 HEBON,29,133 Peter Devilee,30,31 Maaike P G Vreeswijk,32 Jan Lubinski,33 Anna Jakubowska,33 Jacek Gronwald,33 Tomasz Huzarski,33 Tomasz Byrski,33 Bohdan Górski,33 Cezary Cybulski,33 Amanda B Spurdle,6 Helene Holland,6 kConFab,34,133 David E Goldgar,35 Esther M John,36 John L Hopper,37 Melissa Southey,37 Saundra S Buys,38 Mary B Daly,39 Mary-Beth Terry,40 Rita K Schmutzler,41,42 Barbara Wappenschmidt,41,42 Christoph Engel,43 Alfons Meindl,44 Sabine Preisler-Adams,45 Norbert Arnold,46 Dieter Niederacher,47 Christian Sutter,48 Susan M Domchek,49 Katherine L Nathanson,49 Timothy Rebbeck,49 Joanne L Blum,50 Marion Piedmonte,51 Gustavo C Rodriguez,52 Katie Wakeley,53 John F Boggess,54 Jack Basil,55 Stephanie V Blank,56 Eitan Friedman,57 Bella Kaufman,58 Yael Laitman,57 Roni Milgrom,57 Irene L Andrulis,59,60,61 Gord Glendon,59 Hilmi Ozcelik,60 Tomas Kirchhoff,62,63 Joseph Vijai,62,63 Mia M Gaudet,64,65 David Altshuler,66 Candace Guiducci,66 SWE-BRCA,67,133 Niklas Loman,68 Katja Harbst,68 Johanna Rantala,69 Hans Ehrencrona,70 Anne-Marie Gerdes,71 Mads Thomassen,72 Lone Sunde,73 Paolo Peterlongo,74,75 Siranoush Manoukian,76 Bernardo Bonanni,77 Alessandra Viel,78 Paolo Radice,74,75 Trinidad Caldes,79 Miguel de la Hoya,77 Christian F Singer,80 Anneliese Fink-Retter,80 Mark H Greene,81 Phuong L Mai,81 Jennifer T Loud,81 Lucia Guidugli,2 Noralane M Lindor,82 Thomas V O Hansen,83 Finn C Nielsen,83 Ignacio Blanco,84 Conxi Lazaro,84 Judy Garber,85 Susan J Ramus,86 Simon A Gayther,86 Catherine Phelan,87 Stephen Narod,88 Csilla I Szabo,2 MOD SQUAD,89,133 Javier Benitez,90 Ana Osorio,90 Heli Nevanlinna,91 Tuomas Heikkinen,91 Maria A Caligo,92 Mary S Beattie,93,94,95 Ute Hamann,96 Andrew K Godwin,39 Marco Montagna,97 Cinzia Casella,97 Susan L Neuhausen,98 Beth Y Karlan,99,100 Nadine Tung,101 Amanda E Toland,102 Jeffrey Weitzel,103 Olofunmilayo Olopade,104 Jacques Simard,105,106 Penny Soucy,105 Wendy S Rubinstein,107 Adalgeir Arason,108 Gad Rennert,109 Nicholas G Martin,110 Grant W Montgomery,110 Jenny Chang-Claude,111 Dieter Flesch-Janys,112 Hiltrud Brauch,113,114 GENICA,115,133 Gianluca Severi,116 Laura Baglietto,116 Angela Cox,117 Simon S Cross,118 Penelope Miron,119 Sue M Gerty,7 William Tapper,7 Drakoulis Yannoukakos,120 George Fountzilas,121,122 Peter A Fasching,123 Matthias W Beckmann,124 Isabel dos Santos Silva,125 Julian Peto,125 Diether Lambrechts,126 Robert Paridaens,127 Thomas Rüdiger,128 Asta Försti,96,129 Robert Winqvist,130 Katri Pylkäs,130 Robert B Diasio,131 Adam M Lee,131 Jeanette Eckel-Passow,3 Celine Vachon,3 Fiona Blows,1 Kristy Driver,1 Alison Dunning,1 Paul P D Pharoah,1 Kenneth Offit,61 V Shane Pankratz,3 Hakon Hakonarson,132 Georgia Chenevix-Trench,6 Douglas F Easton,1 and Fergus J Couch2

Abstract

Germline BRCA1 mutations predispose to breast cancer. To identify genetic modifiers of this risk, we performed a genome-wide association study in 1,193 individuals with BRCA1 mutations who were diagnosed with invasive breast cancer under age 40 and 1,190 BRCA1 carriers without breast cancer diagnosis over age 35. We took forward 96 SNPs for replication in another 5,986 BRCA1 carriers (2,974 individuals with breast cancer and 3,012 unaffected individuals). Five SNPs on 19p13 were associated with breast cancer risk (Ptrend = 2.3 × 10−9 to Ptrend = 3.9 × 10−7), two of which showed independent associations (rs8170, hazard ratio (HR) = 1.26, 95% CI 1.17–1.35; rs2363956 HR = 0.84, 95% CI 0.80–0.89). Genotyping these SNPs in 6,800 population-based breast cancer cases and 6,613 controls identified a similar association with estrogen receptor–negative breast cancer (rs2363956 per-allele odds ratio (OR) = 0.83, 95% CI 0.75–0.92, Ptrend = 0.0003) and an association with estrogen receptor–positive disease in the opposite direction (OR = 1.07, 95% CI 1.01–1.14, Ptrend = 0.016). The five SNPs were also associated with triple-negative breast cancer in a separate study of 2,301 triple-negative cases and 3,949 controls (Ptrend = 1 × 10−7 to Ptrend = 8 × 10−5; rs2363956 per-allele OR = 0.80, 95% CI 0.74–0.87, Ptrend = 1.1 × 10−7).

Pathogenic BRCA1 and BRCA2 mutations confer high risks of breast and ovarian cancer. Variation in risk estimates by degree of family history suggests that these risks are modified by other genetic variants15. Recent studies from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) have demonstrated that common breast cancer susceptibility alleles, identified through genome-wide association studies (GWAS) in the general population69, are also associated with the risk of developing breast cancer in BRCA1 or BRCA2 mutation carriers10,11. However, although five of six alleles were associated with risk of breast cancer for BRCA2 mutation carriers, only two polymorphisms (in the TOX3 and 2q35 regions) were associated with risk for BRCA1 carriers. These findings are consistent with the distinct pathology of breast cancer in BRCA1 tumors12,13 and suggest that the genetic variants that modify breast cancer risk for BRCA1 mutation carriers may differ from the modifiers of risk for BRCA2 carriers or for non-carriers.

To search for genetic loci associated with breast cancer in BRCA1 carriers, we conducted a two-stage GWAS. In stage 1, we genotyped 2,500 BRCA1 carriers using the Illumina Infinium 610K array, which included 620,901 SNPs. Mutation carriers were selected on the basis of an invasive breast cancer diagnosis at under 40 years of age (n = 1,250) or the absence of breast cancer when 35 years of age or older (n = 1,250). After quality control exclusions, 2,383 carriers (1,193 unaffected and 1,190 affected) from 20 centers in 11 different countries and 555,616 SNPs were available for analysis (Supplementary Tables 1 and 2). Genotype associations were evaluated using a 1 degree-of-freedom (d.f.) score test for trend, based on modeling the retrospective likelihood of the observed genotypes conditional on the disease phenotypes, stratified by country of residence. A kinship-adjusted version of the score test statistic was used to allow for the dependence between related individuals.

There was little evidence for inflation in the test statistic of association (inflation factor (λ) = 1.036; Supplementary Fig. 1). Ninety-six SNPs were significant at the P < 10−4 level compared with 55.6 SNPs which were expected by chance. In stage 2, we genotyped 86 of these SNPs, seven surrogate SNPs (within 10 kb of the significant SNPs and pair-wise r2 > 0.90) and three additional SNPs in 6,332 BRCA1 carriers. After quality control exclusions, 89 SNPs and 5,986 BRCA1 mutation carriers (3,012 unaffected and 2,974 affected) were used in the stage 2 analysis. The most significant associations were for five SNPs on 19p13 (P < 0.002), which had hazard ratios in the same direction as in stage 1 (Table 1 and Supplementary Table 3). In the combined analysis of stage 1 and 2, there was strong evidence of association14 with breast cancer for these SNPs (P = 2.3 × 10−9 to P = 3.9 × 10−7).

Table 1
Associations with breast cancer risk in BRCA1 mutation carriers for the five most significant sNPs on 19p13

The minor alleles of rs8170 and rs4808611 were associated with an increased breast cancer risk for BRCA1 carriers (per allele HR = 1.26, 95% CI 1.17–1.35 for both SNPs). In contrast, SNPs rs8100241, rs2363956 and rs3745185 were associated with decreased breast cancer risk (HR = 0.84, 95% CI 0.80–0.89 for rs8100241 and rs2363956; HR = 0.86, 95% CI 0.81–0.91 for rs3745185) (Table 1). The HR estimates for rs8170 and rs4808611 were similar in stages 1 and 2, but for rs8100241, rs2363956 and rs3745185, the HRs were stronger in stage 1; this may be due to the sample selection criteria for stage 1 or a ‘winner’s curse’ effect15. There was no evidence of heterogeneity in the HR estimates among the countries of residence in stages 1 and 2 combined (Fig. 1; rs8170, P = 0.10; rs4808611, P = 0.14; rs8100241, P = 0.18; rs2363956, P = 0.17; and rs3745185, P = 0.48).

Figure 1
Forest plots of the associations by country of residence of BRCA1 mutation carriers in the combined stage 1 and stage 2 samples. (a,b) Squares indicate the country specific per-allele HR estimates for SNPs rs8170, rs4808611 (a) and rs8100241, rs2363956 ...

The strength of the association with breast cancer could also be affected by the inclusion of prevalent cases if these SNPs were associated with breast cancer survival. To address this possibility, we excluded breast cancer cases diagnosed with the disease >5 years before study entry. The HR estimates were similar to the overall analysis after this exclusion (Supplementary Table 4). This indicates that the inclusion of prevalent breast cancer cases was unlikely to have influenced the overall results.

To investigate whether any of these SNPs were associated with ovarian cancer risk for BRCA1 carriers, we analyzed the data within a competing risks framework and estimated HR simultaneously for breast and ovarian cancer. There was no evidence of association with ovarian cancer risk for any of the SNPs, and the breast cancer associations were virtually identical to the primary analysis both in terms of significance and in the HR estimates (Table 2). We repeated the breast cancer association analysis after excluding all individuals who developed ovarian cancer either before or after a breast cancer diagnosis. Despite the sample size reduction, the top four SNPs remained significant at P < 10−7 and the HR estimates were identical to the analysis which included individuals with ovarian cancer as unaffected individuals (Supplementary Table 4). We also evaluated ovarian cancer associations after excluding individuals with ovarian cancer who were recruited >3 years after their cancer diagnosis in order to account for a potential survival bias. No significant associations were observed after this exclusion (Ptrend = 0.44 to Ptrend = 0.96 using competing risk analysis). We conclude that the associations with breast cancer were not confounded by the competing risk of ovarian cancer.

Table 2
Competing risk analysis; associations with breast and ovarian cancer risk for BRCA1 mutation carriers in the combined stage 1 and 2 samples

We evaluated the SNP associations by the predicted functional consequences of BRCA1 mutation type1618. Class 1 mutations correspond to loss-of-function mutations and are expected to result in a reduced transcript or protein level due to nonsense-mediated RNA decay, whereas class 2 mutations are likely to generate stable proteins with potential residual or dominant negative function1820. Among class 1 mutation carriers (combined stage 1 and 2, n = 5,732), the five most significant associated SNPs included rs6994019, an intronic SNP in MMP16 on chromosome 8 (Ptrend = 2.9 × 10−6) and four SNPs in the 19p13 region (Ptrend = 7.6 × 10−6 to Ptrend = 1.6 × 10−4). The MMP16 SNP rs6994019 was the ninth most significant SNP in the primary analysis of all mutations combined (Ptrend = 2.7 × 10−4 in stage 1 and 2 combined; Supplementary Table 3). The strongest association with breast cancer risk for carriers of class 2 mutations was at the five SNPs in the 19p13 region (Ptrend = 1.8 × 10−6 to Ptrend = 1.2 × 10−4; Supplementary Table 3). The HR estimates for the five SNPs in 19p13 were larger for class 2 mutations, but the differences between class 1 and class 2 mutations were significant for only rs8170 and rs3745185 (P = 0.03 and P = 0.004, respectively). These differences might reflect a stronger modifying effect on breast cancer risk for tumors retaining residual or dominant negative BRCA1 function.

Tumor estrogen or progesterone receptor status was available for 1,197 breast cancer cases in stage 1 and 2 combined. A case-only analysis revealed significant differences in the associations for the 19p13 SNPs between estrogen receptor–positive and estrogen receptor–negative disease and between estrogen receptor– or progesterone receptor–positive and estrogen receptor– and progesterone receptor–negative disease, particularly for SNPs rs8100241, rs2363956 and rs3745185 (P = 0.002 to P = 0.04; Supplementary Table 5). The OR estimates suggest that these SNPs are more strongly associated with estrogen receptor–negative disease.

The two most significant SNPs (rs8170 and rs4808611) were strongly correlated (r2 = 0.87) in the BRCA1 samples but displayed a low correlation with the other associated SNPs (r2 < 0.23). rs8100241 and rs2363956 were perfectly correlated (r2 = 1), whereas the least significant SNP, rs3745185, had weaker correlations with both sets of SNPs (r2 = 0.17 and r2 = 0.74 with rs8170 and rs8100241, respectively).

To evaluate the contribution of the 19p13 locus to breast cancer risk in the general population, we genotyped rs8170 and rs2363956 in 6,800 breast cancer cases and 6,613 controls from the SEARCH (Studies of Epidemiology and Risk Factors in Cancer Heredity) study in the UK. Neither SNP was associated with overall breast cancer risk (P = 0.65 and P = 0.79; Table 3). However, stratification of tumors by estrogen receptor status indicated that both SNPs were associated with estrogen receptor–negative breast cancer (rs8170, per-allele OR = 1.21, 95% CI 1.07–1.37, P = 0.0029 and rs2363956, OR = 0.83, 95% CI 0.75–0.92, P = 0.0003; Table 3). These effect sizes were similar to the estimated HRs for BRCA1 carriers, consistent with the observation that BRCA1 mutations predispose predominately to estrogen receptor–negative disease. Weaker associations were observed in the opposite direction for estrogen receptor–positive disease (rs8170, per-allele OR = 0.91, 95% CI 0.84–0.98, P = 0.011 and rs2363956, OR = 1.07, 95% CI 1.01–1.14, P = 0.016). Similar patterns were observed when tumors were stratified by progesterone receptor status or estrogen receptor and progesterone receptor status combined (Table 3).

Table 3
Associations with breast cancer risk in the seArCH study overall and by tumor subtype, associations with triple negative breast cancer in the tNBCC study and associations with overall breast cancer risk for BRCA2 mutation carriers

The majority of breast tumors in BRCA1 carriers exhibit a triple-negative (estrogen receptor, progesterone receptor and HER2 negative) phenotype. To evaluate the association of the 19p13 locus with triple-negative disease in the general population, we obtained genotype data for the five SNPs from up to 2,301 cases from 15 centers in six countries involved in the triple-negative breast cancer consortium (TNBCC). Genotype data from up to 3,949 geographically matched controls were also available (Supplementary Table 5). All SNPs were associated with triple-negative breast cancer, and the ORs were comparable to the HRs seen in the BRCA1 carriers and the ORs for estrogen receptor–negative breast cancer seen in the SEARCH population-based study (rs2363956, per-allele OR = 0.80, 95% CI 0.74–0.87, P = 1.1 × 10−7 and rs8170, OR = 1.28, 95% CI 1.16–1.41, P = 1.2 × 10−6; Table 3 and Supplementary Table 5).

Two of the SNPs (rs8170 and rs2366956) were genotyped in 2,486 BRCA2 mutation carriers as part of an ongoing GWAS. Neither SNP was associated with breast cancer risk for BRCA2 carriers (Ptrend = 0.17 and Ptrend = 0.07), but the HR estimates were in line with the ORs estimated for estrogen receptor–positive disease in the SEARCH study (Table 3).

All five SNPs were located in a region that spans 39 kb on 19p13 (Fig. 2). In an analysis for the joint effect of these SNPs on breast cancer risk for BRCA1 carriers, it was not possible to distinguish between rs8170 and rs4808611, as neither SNP improved the model fit significantly when the other was included (P = 0.11 and P = 0.22 for rs8170 and rs4808611, respectively). rs8100241 was retained in preference to rs3745185 (P for inclusion of rs3745185 in model = 0.79). Thus, the most parsimonious model included SNPs rs8170 and either rs8100241 or rs2363956 (P for inclusion = 7.7 × 10−5 and P = 6.7 × 10−5 for rs8170 and rs8100241, respectively) and had a 2 d.f. P = 6.3 × 10−13 for inclusion of both SNPs. This suggests that these associations may be driven by a single causative variant that is partially correlated with all five SNPs. To investigate this further, we evaluated the associations for SNPs identified through the 1000 Genomes Project using imputation. 1,055 SNPs in a 300-kb interval with a minor allele frequency >0.01 in samples of European ancestry, were evaluated. Thirty-one SNPs, none of which were genotyped in stage 1, displayed P < 1.76 × 10−9 (Fig. 2 and Supplementary Table 3). The most significant associations with the imputed genotypes in stage 1 and 2 combined were for eight perfectly correlated SNPs within a 13-kb region (the most significant SNP was rs4808075, P = 9.4 × 10−12; Supplementary Table 3). These SNPs were correlated with the four genotyped SNPs (r2 = 0.37 to r2 = 0.58 based on the 1000 Genomes Project data; Supplementary Fig. 2). This suggests that one or more of these imputed SNPs may be causally associated with breast cancer risk. However, some rare SNPs may have been missed because the 1000 Genome Project data used were based on the resequencing of only 56 individuals. Therefore, the possibility that the association is driven by a rarer variant, or a more cryptic common variant not detected in the resequencing, cannot yet be ruled out.

Figure 2
Above, results of the kinship-adjusted score test statistic (1 d.f.) by position (kb) in stage 1 and 2 samples combined for genotyped and imputed SNPs in the associated region (chromosome 19, positions 17,100–17,400 kb). Genotyped SNPs in stages ...

Of the five genotyped SNPs in the region and the eight most significant imputed SNPs, only rs8170 and rs2363956 were located in coding regions. The smaller 13-kb region, defined by the most strongly associated SNPs, contains three genes: ABHD8 (encoding abhydrolase domain containing 8), ANKLE1 (encoding ankyrin repeat and LEM domain containing 1) and C19orf62. The eight most significant imputed SNPs were clustered in and around ANKLE1, which encodes a protein of undefined function. However, C19orf62, which encodes MERIT40 (Mediator of Rap80 Interactions and Targeting 40 kD), is a more plausible genetic modifier of breast cancer in BRCA1 carriers because MERIT40 interacts with BRCA1 in a protein complex. MERIT40 is a component of the BRCA1 A complex containing BRCA1-BARD1, Abraxas1, RAP80, BRCC36 and BRCC45 that is required for recruitment and retention of the BRCA1-BARD1 ubiquitin ligase and the BRCC36 deubiquitination enzyme at sites of DNA damage2123. Thus, a variant that modifies MERIT40 function or expression might influence BRCA1-dependent DNA repair and checkpoint activity in mammary epithelial cells of BRCA1 carriers sufficiently, before loss of the wildtype BRCA1 allele, to increase the risk of breast cancer. However, until the SNPs that increase risk of cancer have been definitively linked to MERIT40, it remains possible that the other genes in the region or genes influenced by long range chromatin remodeling or by transcriptional events account for the breast cancer association.

Genetic variation at this locus, in combination with other risk modifiers, may prove useful in individual cancer risk assessment for breast cancer in BRCA1 carriers. In addition, understanding the functional basis of this association may provide important insights into the etiology of BRCA1-associated breast cancer and hormone receptor–negative breast cancer in the general population. Our results suggest that GWAS in BRCA1 mutation carriers or GWAS restricted to specific breast cancer subtypes may identify further breast cancer susceptibility variants.

METHODS

Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.

Supplementary Material

Supplement

Acknowledgments

Financial support for this study was provided by the Breast Cancer Research Foundation (BCRF), Susan G. Komen for the Cure and US National Institutes of Health grant CA128978 to F.J.C. and by Cancer Research UK to D.F.E. and A.C.A. A.C.A. is a Cancer Research UK Senior Cancer Research Fellow and D.F.E. is a Cancer Research UK Principal Research Fellow. The authors thank Cancer Genetic Markers of Susceptability (CGEMS) and Wellcome Trust Case Control Consortium (WTCCC) for provision of genotype data from controls. Study specific acknowledgments listed in Supplementary Note.

Footnotes

Note: Supplementary information is available on the Nature Genetics website.

AUTHOR CONTRIBUTIONS

F.J.C., A.C.A. and D.F.E. designed the study and obtained financial support. G.C.-T. founded CIMBA in order to provide the infrastructure for the BRCA1 GWAS. F.J.C. and X.W. coordinated collection of samples. A.C.A. directed the statistical analysis. D.F.E. advised on the statistical analysis. C.K., Z.S.F. and T.L. carried out analyses. Z.S.F., R.T., J.M., L.M. and D.B. provided bioinformatics and database support. F.J.C., H. Hakonarson and X.W. directed the genotyping of the BRCA1 carrier and triple-negative samples. M.G. directed the genotyping of the UK case-control samples. A.C.A., F.J.C. and D.F.E. drafted the manuscript. F.J.C. was the overall project leader.

O.M.S. and S.H. coordinated the BRCA1 mutation classification. T.K., J.V., M.M.G., D.A. and C.G. were involved in the BRCA2 GWAS genotyping and coordination. K.O. led the BRCA2 GWAS.

S.P., M.C., C.O., D.F., D.E., D.G.E., R.E., L.I., C.C., F.D., J.P., O.M.S., D.S.-L., C.H., S.M., S.G., C.L., A.R., O.C., A.H., P.B., F.B.L.H., M.A.R., A.J., A.v.d.O., N.H., R.B.v.d.L., H.M.-H., E.B.G.G., P.D., M.P.G.V., J.L., A.J., J.G., T.H., T.B., B.G., C.C., A.B.S., H.H., D.E., E.M.J., J.L.H., M.S., S.S.B., M.B.D., M.-B.T., R.K.S., B.W., C.E., A.M., S.P.-A., N.A., D.N., C.S., S.M.D., K.L.N., T.R., J.L.B., M.P., G.C.R., K.W., J.F.B., J.B., S.V.B., E.F., B.K., Y.L., R.M., I.L.A., G.G., H.O., N.L., K.H., J.R., H.E., A.-M.G., M.T., L.S., P.P., S.M., B.B., A.V., P.R., T.C., M.d.l.H., C.F.S., A.F.-R., M.H.G., P.L.M., J.T.L., L.G., N.M.L., T.V.O.H., F.C.N., I.B., C.L., J.G., S.J.R., S.A.G., C.P., S.N., C.I.S., J.B., A.O., H.N., T.H., M.A.C., M.S.B., U.H., A.K.G., M.M., C.C., S.L.N., B.Y.K., N.T., A.E.T., J.W., O.O., J.S., P.S., W.S.R., A.A. and G.R. collected data and samples on BRCA1 and or BRCA2 mutation carriers.

N.G.M., G.W.M., J.C.-C., D.F.-J., H.B., G.S., L.B., A.C., S.S.C., P.M., S.M.G., W.T., D.Y., G.F., P.A.F., M.W.B., I.d.S.S., J.P., D.L., R.P., T.R., A.F., R.W., K.P., R.B.D., A.M.L., J.E.-P., C.V., F.B., K.D., A.D. and P.P.D.P. collected data and samples for the TNBCC case-control and/or the SEARCH studies.

All authors provided critical review of the manuscript.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Reprints and permissions information is available online at http://npg.nature.com/reprintsandpermissions/.

References

1. Antoniou A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130. [PubMed]
2. Antoniou AC, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008;98:1457–1466. [PMC free article] [PubMed]
3. Begg CB, et al. Variation of breast cancer risk among BRCA1/2 carriers. J Am Med Assoc. 2008;299:194–201. [PMC free article] [PubMed]
4. Milne RL, et al. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res. 2008;14:2861–2869. [PubMed]
5. Simchoni S, et al. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci USA. 2006;103:3770–3774. [PubMed]
6. Easton DF, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447:1087–1093. [PMC free article] [PubMed]
7. Hunter DJ, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39:870–874. [PMC free article] [PubMed]
8. Stacey SN, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancer. Nat Genet. 2007;39:865–869. [PubMed]
9. Stacey SN, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer. Nat Genet. 2008;40:703–706. [PubMed]
10. Antoniou AC, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008;82:937–948. [PubMed]
11. Antoniou AC, et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2009;18:4442–4456. [PMC free article] [PubMed]
12. Lakhani SR, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20:2310–2318. [PubMed]
13. Lakhani SR, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11:5175–5180. [PubMed]
14. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–678. [PMC free article] [PubMed]
15. Zollner S, Pritchard JK. Overcoming the winner’s curse: estimating penetrance parameters from case-control data. Am J Hum Genet. 2007;80:605–615. [PubMed]
16. Buisson M, Anczukow O, Zetoune AB, Ware MD, Mazoyer S. The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Hum Mutat. 2006;27:1024–1029. [PubMed]
17. Mazoyer S, et al. A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet. 1998;62:713–715. [PubMed]
18. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet. 2002;11:2805–2814. [PubMed]
19. Antoniou AC, et al. RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007;81:1186–1200. [PubMed]
20. Liu HX, Cartegni L, Zhang MQ, Krainer AR. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet. 2001;27:55–58. [PubMed]
21. Feng L, Huang J, Chen J. MERIT40 facilitates BRCA1 localization and DNA damage repair. Genes Dev. 2009;23:719–728. [PubMed]
22. Shao G, et al. MERIT40 controls BRCA1-Rap80 complex integrity and recruitment to DNA double-strand breaks. Genes Dev. 2009;23:740–754. [PubMed]
23. Wang B, Hurov K, Hofmann K, Elledge SJ. NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. Genes Dev. 2009;23:729–739. [PubMed]